Symbols

AVNS

Avanos Medical·NYSE

--(--)

AVNS fundamentals

AVNS Q4 2025 Earnings

Avanos Medical (AVNS) released its earnings on Feb 24, 2026: revenue was 180.90M (YoY +0.72%), beat estimates; EPS was 0.29 (YoY -32.56%), beat estimates.

Revenue / YoY

180.90M

+0.72%

EPS / YoY

0.29

-32.56%

Report date

Feb 24, 2026

AVNS Earnings Call Summary for Q4,2025

Revenue Growth: Full year net sales of $701M, exceeding guidance, with SNS up 8% organically and PM&R at 2.3% normalized growth.
Tariff Mitigation: $30M tariff impact in 2026, with 2/3 from China; full exit by June 2026 to improve gross margin in H2.
Segment Strength: SNS driven by double-digit short-term feeding growth; PM&R RFA business up double digits, offsetting surgical pain challenges.
Financial Health: $90M cash, $43M free cash flow in 2025; 2026 guidance for $700-720M net sales and $0.90-1.10 EPS.
Strategic Moves: Divestitures, Nexus acquisition, and GAME READY restructuring to enhance profitability and focus on core channels.

Earnings

EPS

Revenue

Revenue & Expenses

AVNS has released its 2025 Q4 earnings report, with revenue of 180.90M, reflecting a YoY change of 0.72%, and net profit of -1.30M, showing a YoY change of 99.67%. The Sankey diagram below clearly presents AVNS's revenue sources and cost distribution.

Key Indicators

Avanos Medical (AVNS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Avanos Medical (AVNS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Avanos Medical (AVNS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Avanos Medical (AVNS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown